BioSpace News Archive

Genetown

Cerevance Announces Presentation at Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development

Cerevance today announced plans to present at the upcoming Neurodegeneration: New Biology Guiding the Next Generation of Therapeutic Development conference, taking place in British Columbia, Canada, May 15 – 19, 2023.

May 9, 2023
·
1 min read
Pharm Country

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within the Sports and Spine Clinic in Oregon

Milestone Scientific Inc. today announced that it has commenced sales of CompuFlo ® Epidural disposables into The Sports and Spine Center in Tualatin, Oregon.

May 9, 2023
·
4 min read
FDA

SAB Biotherapeutics Announces Progress on U.S. FDA’s Phased Review of Company’s Groundbreaking DiversitAb™ Platform

SAB Biotherapeutics today announced the U.S. Food and Drug Administration has approved five of seven sections required for the Company’s pending New Animal Drug Application (NADA) for the company’s antibody-generating platform in Transchromosomic (Tc) bovine.

May 9, 2023
·
7 min read
Business

Vicinitas Therapeutics Appoints Christian Hofmann, Ph.D., as Chief Executive Officer

Vicinitas Therapeutics today announced that Christian Hofmann, Ph.D., has been appointed as the company’s Chief Executive Officer and member of the board of directors.

May 9, 2023
·
3 min read
Genetown

Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress

Fractyl Health to Present Preclinical Proof-of-Concept Data for Rejuva ® Pancreatic Gene Therapy Platform Program at the American Society of Gene & Cell Therapy Congress.

May 9, 2023
·
4 min read
Drug Development

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study ( NCT05658107 ) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.

May 9, 2023
·
3 min read
Business

AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast

AIM ImmunoTech Inc. announced today that management will host a conference call and webcast to discuss the Company’s Q1 2023 operational and financial results on Tuesday, May 16, 2023 at 8:30 AM ET.

May 9, 2023
·
1 min read
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it will participate in the Alliance Global Partners’ Virtual Healthcare Conference being held May 23-24, 2023.

May 9, 2023
·
1 min read
Business

Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease

Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan’s proprietary target discovery platform, TargetScan, to identify the antigens recognized by T cells in patients with Crohn’s disease.

May 9, 2023
·
12 min read
Biotech Bay

Interim Results of Study That Used Non-invasive Wireless Patches to Monitor Myoelectric Activity of Crohn’s Disease Patients in Flare and Remission

G-Tech Medical, a developer of non-invasive diagnostic solutions for patients with gastrointestinal disorders, today announced presentation of a poster at the Digestive Disease Week Annual Meeting held in Chicago May 6-9.

May 9, 2023
·
2 min read